510(k) K233986
K233986 is an FDA 510(k) premarket notification submitted by Becton, Dickinson and Company for the device "BD Phoenix Automated Microbiology System - GN Ciprofloxacin (0.01564 µg/mL)". The FDA issued a decision of Substantially Equivalent on March 15, 2024. The device falls under product code LON (System, Test, Automated, Antimicrobial Susceptibility, Short Incubation), a Class II device regulated under 21 CFR 866.1645. Becton, Dickinson and Company has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- March 15, 2024
- Date Received
- December 18, 2023
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
- Device Class
- Class II
- Regulation Number
- 866.1645
- Review Panel
- MI
- Submission Type